[CANCER RESEARCH 50, 4177-4189. July 15, 1990] Special Lecture Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture1 Leonard J. Lerner and V. Craig Jordan Department of Pharmacology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [L. J. L.J, and Departments of Human Oncology and Pharmacology, University of Wisconsin Clinical Cancer Center, Madison, Wisconsin 53792 [V. C. J.J Abstract This paper describes the laboratory discovery and clinical testing of the first nonsteroidal antiestrogen, MER-25 (ethantoxytriphetol). The compound blocks estrogen action in all species tested and has only slight but transient estrogenic effects. No other antisteroidal actions are noted. MER-25 is antiestrogenic in primates and was investigated in the clinics in a wide range of gynecological conditions, including breast and endometrial cancer. Unfortunately toxic side effects (hallucinations, etc.) precluded further investigation. A derivative of triphenylethylene, clomiphene, has some partial agonist (estrogen-like) actions in laboratory animals and following clinical evaluation is now an established agent for the induction of ovulation in subfertile women. Although clomiphene is active in advanced breast cancer, it was not developed further. In the late 1960s a related compound, tamoxifen, was evaluated to treat a number of estrogen-responsive disorders but was successfully introduced in the 1970s for the treatment of advanced breast cancer. Although there was only modest initial interest in the palliative use of tamoxifen, an enormous increase in basic and applied studies with antiestrogens resulted in a definition of the target site-specific and tumoristatic actions of tamoxifen. Close cooperation between laboratory and clinical evaluation has guided the subsequent development of tamoxifen which is now available to treat all stages of breast cancer. Long-term adjuvant tamoxifen therapy, a concept developed in the laboratory, is currently the treatment strategy of choice. The considerable success of tamoxifen has focused attention on new antiestrogens with different pharmacological properties for other potential clinical applications. Introduction Estrogen is involved in a large number of physiological phe nomena throughout the body. The mechanism by which this hormone produces its effects is complex and may not be uni versal for all of the activities reported to be estrogenic. Estrogen is also involved in some pathologies. Here too, its role has not been completely defined. The removal of estrogen or interfer ence with its action is helpful in elucidating the role of estrogen and the mechanism of its activity in both physiological and pathological processes. Perhaps the earliest association of reproductive tissue and behavioral responses to a hormonal secreting organ was the cessation of estrus in domesticated animals following ovariectomy and the diminution of aggressive behavior in male animals and humans after castration. Indeed, almost 100 years ago there was recognition that the ovary was involved in mammary car cinoma and that removal of that endocrine gland could be beneficial to the patient (1). Ablation of other endocrine organs including adrenalectomy (2) and hypophysectomy (3) were also found to be beneficial in some breast cancers. Surgical removal of these glands or the ovaries, however, did more than decrease or eliminate endoge nous estrogen from the body. A number of hormones and nonhormonal substances were removed, some of which were Received 4/5/90. 1Presented at the 80th Annual Meeting of the American Association for Cancer Research, May 24, 1989, San Francisco, CA. not involved in the pathology. However, it is reasonable to expect a complex tissue such as the mammary gland, which requires a number of hormones and probably growth factors for its normal growth and function, to have the involvement of more than one hormone in its pathology. Certainly there are a number of possible ways of interfering with estrogen interaction with its target tissue other than by removing the steroid-secreting glands. Reduction of pituitary gonadotropin secretion by sex steroids or by blocking the bioconversion of androgen to estrogen are ways of decreasing the endogenous pool of estrogens. Biologically available estrogen can also be reduced by increased catabolism or altering the plasma level of estrogen-binding protein. Another way to inter fere with estrogen activity is to block it at the level of its receptor in estrogen target tissues. Development of Nonsteroidal Estrogens The most common of the wide spectrum of biological activi ties associated with estrogens, regardless of chemical classifi cation or source, is the uterotrophic response and the cornification of vaginal epithelium. These activities have been incor porated into the bioassays that have defined every natural and synthetic compound designated as an estrogen. Development of a sensitive bioassay in rodents by Allen and Doisy (4) enabled characterization and classification according to potency of the natural steroidal estrogens and nonsteroidal plant estrogens. This formed the basis to identify the structural requirements for activity, as well as potency. Cook et al. (5) found that the phenanthrene nucleus was not necessary for estrogenic activity. The laboratory of Dodds and his collaborators therefore synthesized a large number of diphenolic and triphenolic compounds resulting in the develop ment of potent, clinically important estrogenic substances such as diethylstilbestrol (6), hexestrol, and dienestrol (7). At this same time in the mid-1930s, Robson and Schonberg reported that triphenylethylene had estrogenic activity (8) and that oral potency and prolongation of activity could be achieved by bromination (9). This finding led, in the 1940s, to the synthesis of a number of triphenylethylene derivatives including more potent halogenated compounds by the William S. Merrell Co. in the United States (10, 11) and by Imperial Chemical Indus tries in the United Kingdom. While all of the compounds called estrogens increase uterine weight and stratify and cornify the vaginal epithelium, the spectrum of other biological activities associated with estradiol may or may not be present in all of these estrogens. Moreover, the quantitative aspect of one of the activities may not be related to other activities of the same compound. Knowledge of structure-activity relationships allows for the rational design of chemical agents with greater specificity for a particular pharmacological action. Some of the physiological interactions of the steroidal hor- 4177 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER mones were known in the first half of the 20th century. These interactions could be additive, augmentative, synergistic, or antagonistic depending upon the particular steroids, dosage of each, order and time course of administration, as well as the end point and species of animal under study. A small dose of an estrogen administered to an immature rabbit prior to treat ment with progesterone allows for maximal growth and devel opment of the uterus. It is now known that this effect is a result of increased estrogen-induced uterine hyperemia and induction of proges terone receptors. Large doses of the estrogen, however, can reduce the subsequent effect of the progestational agent in the rabbit. ETHAMOXYTRIPHETOL (MER 25) Estrogen Antagonism Treatment of an immature or ovariectomized rodent with a progestogen, androgen or corticoid can antagonize the uterotrophic effect of estrogens (12-16). Antagonism, however, is closely linked to the relative and absolute dose of the agonist and the antagonist. The first estrogens that demonstrated antagonism of the stimulation of another estrogen were estriol (17) and 16-epiestriol (18). These weak estrogenic steroids partially inhibited the uterotrophic effect of estradiol in the rat. This antiestrogenic activity was manifested only over a narrow range of doses (19), and at lower doses the two estrogens induced additive uterine growth responses (20). Moreover, for the end point of vaginal cornification in rats and mice, estriol was always additive with estradiol (21). The nonsteroidal synthetic estrogens and their structurally related weak or inactive relatives were an attractive source in the search for modulators or inhibitors of estrogenic activity. Several weakly estrogenic stilbene and triphenylethylene com pounds demonstrated partial antagonism of estrone- or estradiol-induced uterotrophic activity in mice in my laboratory (L. J. L.). At a presentation of data (22) on the antiestrogenic activity of one of the diphenolic compounds Dr. Roy Hertz from the NIH remarked that the findings were interesting but a clinically useful antiestrogen would have to be much more potent. Discovery and Development of Ethamoxytriphetol (MER-25) In 1954, a compound related to triphenylethylene and chlorotrianisene was synthesized at Merrell to study its possible cardiovascular effects, but it was found to be inactive. The structural similarities ofthat compound to those of the triphenylethylenes that were being studied for antiestrogenic activity in my laboratory (L. J. L.) prompted us to test its endocrine activity. That compound, l-/?-2-(diethylamino)ethoxyphenyl-2-(/>methoxyphenyl)-l-phenylethanol was later given the generic name of ethamoxytriphetol and the reference designation of MER-25 (Fig. 1). The initial dose of MER-25 was selected on the basis of experience that showed that even the most active of the compounds tested up to that time were of low potency and only partially inhibited the uterotrophic effect of estrone or estradiol. Weanling mice were given s.c. injections of MER-25 in olive oil for 3 days at a daily dose of 1.7 mg (170 mg/kg). One-half of the animals were also given daily injections of estradiol benzoate (0.1 ^g/animal). The results of this experiment were surprising since the uterine weights of the mice that had been N1TROMIPHENE (CN-55, 945) NAFOXIDINE(U-11,100A) TAMOXIFEN (ICI 46, 474) Fig. 1. Structures of MER-25 and antiestrogens derived from triphenyleth ylene. given MER-25 with or without estradiol benzoate were identical to those of animals given injections of the olive oil alone. In addition, uterine vascularity and intraluminal fluid, which also increases with estrogen treatment, were absent in the MER-25treated groups. Moreover, body weight remained normal. The study was repeated several times and the complete blockade of the estrogen-induced uterotrophic response was confirmed. The inhibition of estradiol action in the mouse uterus by MER-25 was dose related and simultaneous administration of graded doses of estradiol was able to prevent the antiestrogenic effects of MER-25 in a dose-related manner (Fig. 2). This study demonstrated that MER-25 is a competitive antagonist of es trogen action. The nature of the competitive mechanism of this and deriv ative antiestrogens was elucidated when Jensen et al. (23, 24) found that they prevented binding of labeled estradiol to the rat uterus. Numerous studies in vivo and in vitro have confirmed that the nonsteroidal antiestrogens act at the level of the estro gen receptor. However, the exact nature of the mechanism(s) is still incompletely understood. Moreover, other activities have been documented for this class of pharmacological agents. These include inhibition of estrogen-induced protein synthesis, thymidine incorporation, DNA synthesis, cell cycle blockage at the GÃ¬phase, inhibition of calmodulin, and non-estrogen-re lated events. Not all of these activities, however, have been found univer sally with all antiestrogens and results from studies in vivo do not necessarily support findings in vitro. Some of these effects may be a result of the relative estrogenic to antiestrogenic activities of the compound studied or to the biological half-life of each activity. A comparison of an estrogenic antiestrogen 4178 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER 50 (11F) ~. O) Estradiol 0.3 Mg 33 (16F,3P,4N) 40 (11F) (1N,3P,7F) (9N,1P,1F) Fig. 2. Uterotrophic and antiestrogenic ac tivities of MER-25 in immature mice. Groups of animals were treated for 3 days with (A) estradici benzoate (0.3 ng) and MER-25 (O) or MER-25 alone (A) or (B) different doses of estradici benzoate with (d) or without (â€¢)5 mg MER-25. All doses are 3-day total dosages. Data in paren theses, number of animals exhibiting full (/"), l 30 (1N.7P.2F) ^ /> 4N.4P.3F) 20 partial (P), or no (AOuterine intraluminal fluid. 'Control n rControl (25N) (1P.33N) (38N) I TOTAL 0.2 1.0 DOSE MER-25 (partial agonist) with a nonestrogenic antiestrogen (pure antag onist) for each of the activities may help resolve this problem. The antiuterotrophic effect of MER-25 was also demon strated in immature, ovariectomized, and adult rats (25-30). In the immature rat, a MER-25:estradiol benzoate ratio of 400:1 reduced the Uterotrophic effect of the estrogen by approximately 45% and complete suppression of the estrogen activity was obtained with a ratio of 10,000:1 (Fig. 3). Uterine as well as oviductal growth stimulated by estradiol was inhibited in a dose-related fashion as were a number of biochemical parame ters elevated by estrogen. These included nucleic acids, phospholipids, glucose-6-phosphate dehydrogenase and other en zyme activities, nitrogen, and water. These initial studies prompted my colleagues and I (L. J. L.) to investigate the pharmacological spectrum of activities of MER-25 in different species in various stages of maturity. Our studies evaluated the antihormonal and antifertility properties of MER-25 in acute and long-term studies (15, 26). Each study brought new information but also raised new questions. MER25 was an antiuterotrophic agent regardless of the route of administration or the estrogen used as the agonist, but it had little or no activity as an antagonist of androgen or progester one-induced Uterotrophic activity. 140 Total Dose of MER-25 - mg Fig. 3. Uterotrophic and antiestrogenic activities of MER-25 in ovariecto mized immature rats. Groups of animals were treated for 4 days with a total dose of 2.0 fig estradiol benzoate ( ), MER-25 <&\,estradiol benzoate plus MER25 (â€¢)or injection vehicle (sesame oil) alone ( ). Animals were killed on day 5 and blotted uteri were weighed wet. (mg) 5.0 0.03 TOTAL 30.0 0.3 DOSE ESTRADIOL 3000 <M9> MER-25 was also a complete inhibitor of the effect of endog enous estrogen or administered estrogen at the level of the vagina. Cornification of vaginal epithelium by estrogen was blocked and MER-25 did not induce any cornification when administered to immature or ovariectomized mice or rats, dem onstrating a lack of inherent estrogenicity. Further Studies with MER-25 There was some evidence that this compound did posses very weak and short-lived estrogen activity at other end points. At relatively low doses, it induced a weak Uterotrophic effect which, many times, was only borderline in significance. When a single dose of this agent was administered to immature mice, a slight increase in uterine weight was noted 48 h after treatment but was not seen on subsequent days (26). Those doses that were weakly Uterotrophic also elevated uterine alkaline phosphatase (27). In immature rats, lower doses induced minimal increases in uterine weight (28). Low doses of MER-25 induced a short lived increase in glucose-6-phosphate dehydrogenase, glucose isomerase, and lipids (30). In the immature rabbit pretreated with estrogen to allow for progesterone-induced endometrial development, MER-25 effectively inhibited the estrogen activity (presumed induction of progesterone receptors), thereby blunt ing the effect of the progesterone (26). MER-25, however, when administered instead of estradiol, permitted a weak uterine growth response to subsequent progesterone treatment. Other indications of weak estrogenic activity were the acceleration of vaginal opening in prepuberal rats and mucification of the adult rat vagina (26, 27). Offspring of rats treated with MER-25 during the last third of gestation demonstrated early opening of their vaginas (27). MER-25 has only weak antigonadotropin activity, but it effectively blocks estrogen- or castration-induced pituitary hy pertrophy and gonadotroph degranulation (26). It was found to be devoid of any other hormonal activity. Mouse uteri stimulated by testosterone were unaffected by simultaneous treatment with this estrogen antagonist (26, 27). High doses of MER-25, however, partially inhibited androgenstimulated uterine weight increase and biochemical changes in the immature rat (29). Immature castrated male rats given injections of MER-25 and testosterone propionate demon strated no antagonism of the androgen-induced changes in the seminal vesicles although there was a partial inhibition of the 4179 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER augmented weight and nucleic acids of the ventral prostate (32). Antiestrogenic activity was also found in the chick. MER-25 inhibited estrogen-induced oviductal growth and elevated plasma phospholipids (26). MER-25 did not alter these same estrogen target parameters at any dose used, indicating a lack of estrogenicity in this species. Tamoxifen and other triphenylethylene antiestrogens (33, 34) were later also found to be devoid of estrogen activity in the chick oviduct. This is confirm atory evidence for a species-related hormonal profile for this chemical class of compounds. MER-25, if it were to have clinical potential, had to have antiestrogenic activity in a primate. Ovariectomized Macaca mulatta monkeys, maintained on estradici, were periodically given varying p.o. doses of MER-25. The antagonist induced a sharp reduction in the cornified vaginal cells of these estrogenized animals and at higher doses the decrease in cornified cells was to the castration level. Accompanying this was a lessening of the sex skin swelling and reddening and eventually estrogen withdrawal bleeding (26). Other studies in intact cycling mon keys demonstrated that endogenous estrogen was inhibited by antagonism or via reduced gonadotropin secretion since the menstrual cycles were lengthened and the percentage of corni fied cells in the vaginal smear decreased. These studies paralleled those in intact rats where a daily p.o. dose of 1 mg lengthened the estrous cycle and 5 mg/day stopped cycling (26). The rats resumed normal cycling of 2-6 days following the last dose. This prototype antiestrogen was further investigated in order to determine its pharmacological properties especially in rela tion to those biological phenomena where endogenous estrogen or gonadotropins had been shown to be involved. Effect of Antiestrogens on Reproduction The reproductive system and all of its accessory tissues re quire a changing balance of hormones for their development and function. Changes in the absolute and relative quantities of these hormones may lead to functional disorders and pathology. Treatments that increase or decrease the available pool of the particular hormone or alter its activity may correct the problem. Similarly a physiological process such as ovulation can be interrupted by addition of hormones. It was interesting to explore the actions of MER-25, an antiestrogen having weak gonadotropin-inhibitory and very weak selective estrogenic activities, on reproduction. The com pound was administered to female rats at various times prior to or after mating (26, 27). None of the pretreated animals mated, since none of the animals exhibited estrus behavior or showed vaginal cornification. Treatments that were initiated after mating on day 1 of pregnancy probably inhibited nidation or altered ova transport since no fetuses or products of concep tion were found. Administration of the compound on days 4-7 postmating prevented blastocyst implantation. When treatment was delayed until the 13th day of pregnancy, gestation contin ued and live pups were delivered, but parturition was delayed and was difficult with several of the young dying probably due to the effects of estrogen deprivation on uterine contraction. The postcoital antifertility effect of MER-25 was confirmed by other investigators (35, 36) and similar results were obtained for other triphenylethylene antiestrogens including clomiphene and MRL-37 in my laboratories (L. J. L.) and by other inves tigators (37, 38). None of the antiestrogenic agents were suffi ciently efficacious in primates, although ovum implantation in the monkey uterus was inhibited by several (39) and at least one such agent was developed for postcoital antifertility utility (40), but it was never marketed. MER-25 was also shown to augment pregnancy maintenance by progesterone in Ovariectomized rats similar to that obtained with estrone (27). However, in rats fed a protein-free diet where estrone helps maintain pregnancy, the administration of MER25 negated the supportive effect of the estrogen (27). The activities of MER-25 were expressed relative to the hormonal and developmental state of the animal. In adult cycling rats, this compound decreased the weights and function of the ovaries, pituitary, and uterus. It also antagonized the effect of estrogen on the latter two organs (26). Administration of MER-25 to pubertal rats, however, produced different re sults. Ovarian weights, nucleic acids, and enzyme activities were elevated after 4 days of treatment (41). The increases in the ovaries were similar to that obtained by treatment with human chorionic gonadotropin (41). Estradici treatment at the same time prevented the MER-25-induced augmentation of ovarian weight and biochemical activities. The increase in ovarian activity following MER-25 treatment of the pubertal rat may parallel the ovarian stimulation in women after administration of antiestrogens including MER25 and clomiphene citrate. Utility of Antiestrogens for Ovulation Induction In the 1950s Dr. James H. Leathern used the human cho rionic gonadotropin-treated hypothyroid rat as a model for polycystic ovaries. His work stimulated us to study the effect of MER-25 in this model. The antiestrogen blocked the uterine hypertrophy induced by the hyperactive ovary and reduced ovarian weight; however, cystic follicles were still evident. These studies were repeated and extended by Leathern and his grad uate students. MER-25 prevented the induction of cystic ovaries and alteration in ovarian ascorbic acid concentration (42). Fur thermore, pretreatment with MER-25 prior to induction of the hypothyroid state followed by gonadotropin administration was also effective in blocking cystic development (43). A preliminary study in nymphomaniac cows bearing cystic ovaries was performed by W. Hansel and R. M. Melampy using a low use of MER-25 that I (L. J. L.) had suggested. These cows promptly resumed normal behavior; however, no meas urement of ovarian follicular size or ovulation was recorded. These findings in animals encouraged us to initiate explora tory studies on selected patients to determine the effects of MER-25 on menstrual or ovarian disorders. Kistner and Smith (44) reported that patients treated for endometrial hyperplasia and carcinoma with MER-25 demonstrated higher urinary ex cretion of estrogen and follicle-stimulating hormone and had temperature changes indicative of ovulation. These investiga tors also induced ovulation with this compound in patients with Stein-Leventhal syndrome (45). At this same time Tyler et al. (46) reported that 6 of 18 patients with severe anovulatory problems ovulated within 7 days of starting MER-25 therapy. This antiestrogen, however, induced undesirable and unex pected central nervous system symptoms leading to cessation of its use. Fortunately my laboratory (L. J. L.) had been devel oping, at the same time, another related but more potent antiestrogen that had some qualitative differences from MER25. That compound, MRL-41 or clomiphene citrate (47) (orig inally called chloramiphene) (Fig. 1), was, in comparison to MER-25, weakly estrogenic (25). Clomiphene was provided to R. W. Kistner, E. T. Tyler, and R. B. Greenblatt to study its ability to induce ovulation. Shortly thereafter Greenblatt et al. 4180 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER (48) reported that this compound successfully induced ovulation in women and similar successes were reported by the other investigators. Ovulation was induced with doses that were smaller than those used for MER-25 and no central nervous system disturbances were found. These studies ushered in a new mode for treating anovulatory and infertile patients having functional ovaries which has had widespread use in in vitro fertilization technology. Effect of Antiestrogens on Lipids Estrogens are known to regulate the synthesis and metabo lism of lipids. This produces a change in the relative concentra tion of various lipid fractions in the plasma and disposition in tissues. Indeed endogenous estrogen is a normal protective regulator for the cardiovascular system and the decreased syn thesis of these steroids at menopause is associated with an increase in atherosclerosis and coronary disease. Men are more prone to these disorders than are premenopausal women. A chemical compound that demonstrates an estrogen-like activity on lipids without affecting the reproductive system would there fore be desirable. Another possible partitioning of the biological spectrum of activities of estrogen might result from the admin istration of an estrogen such as estradiol and of a "nonestrogenic" antiestrogen. An experiment in 1-week-old chicks showed that estradiol benzoate could increase oviductal weight by 1500% while dou bling the plasma phospholipid concentration. MER-25 admin istration did not alter either end point even at doses 300 times larger than that of the estrogen. When both substances were administered to these birds the estrogenic effect on the plasma phospholipids as well as on the oviduct were blocked (26). Even though MER-25 failed to show an estrogen-like effect on the chick plasma phospholipids, this antiestrogen and a number of other compounds having different spectra of estro genic and/or antiestrogenic activities were investigated in the rat. MER-25, clomiphene citrate, and a related compound, triparanol, were hypocholesterolemic (41) with the latter com pound being 5 times more potent than the other two. Studies in vitro with rat liver homogenates demonstrated that MER-25 and clomiphene inhibited the conversion of mevalonate to cholesterol whereas triparanol produced its major blocking effect after mevalonic acid (41, 49). The nonestrogenic weak antiestrogen 2,2'"-(l-methyl-4,4diphenylbutylidene)bis(/>-phenyleneoxy)bistriethylamine oxalate lowered plasma cholesterol in rats fed normal and hyperlipemic diets by blocking cholesterol biosynthesis between mev alonate and lanosterol (49). It also reduced serum free fatty acids and triglycÃ©rides. It may be interesting to investigate the relationship of cho lesterol biosynthesis inhibition and anticancer potential of the antiestrogens in light of present knowledge concerning the catalogue of factors required for cellular growth, development, regulation, and multiplication. Demonstration Cancer of the Efficacy of an Antiestrogen in Breast Laboratory studies with MER-25, clomiphene, and many other related compounds suggested a variety of potential clinical utilities based on the particular pharmacological spectrum of each compound. In mid-1956 a list of some of these utilities was suggested for evaluation with MER-25. These included, "1) precocious development, 2) anti-fertility, 3) habitual abor tion, 4) fertility in the female, 5) dysmenorrhea, 6) all kinds of menstrual disturbances including menorrhagia or prolonged menstrual periods, 7) menopause, 8) endometriosis, 9) acne, 10) cancerâ€”a) to test for or substitute for adrenalectomy in cancer, b) as a substitute for ovariectomy, c) mammary carci noma, d) prostatic cancerâ€”alone or in combination with an estrogen, in an attempt to maintain the effects of estrogen on the prostate and avoid side reactions of estrogens, 11) benign prostatic hypertrophy, 12) postpartum breast engorgement, and 13) precipitate the menopause when desirable." While that list was compiled largely on the basis of laboratory data on MER-25 presented by L. J. L., it is interesting that the anticancer indications were not derived from animal tumor models since such models were not available. The stimulation for such evaluation in human cancers came largely from the availability of a unique compound that could block the effect of estrogen completely and also have weak gonadotropin inhibi tion activity. Several well known competent clinical investigators were suggested for each of the areas. The two who were asked to investigate MER-25 in breast disorders including cancers were Dr. Roy Hertz at the NIH and Dr. Robert Kistner at Harvard University. The dosages suggested were derived from the labo ratory studies in animals including those performed in the monkey. Dr. Kistner also investigated other diseases of the breast, uterus, and ovaries. Both investigators confirmed antiestrogenic activity in their patients. Kistner and Smith (44) reported that patients with chronic cystic mastitis not only had pain relief but also had reduced glandular proliferation and breast size. He also found that two of four patients with breast carcinomas experienced pain relief and a reduction of calcium excretion while on MER25 therapy. Hertz also treated several patients with metastatic breast cancer and obtained similar favorable results. These studies demonstrated the utility of an antiestrogen in breast cancer. Unfortunately the investigation of MER-25 as a therapeutic agent had to be discontinued because Drs. Hertz, Kistner, and Tyler reported that their patients were experiencing hallucina tions, psychotic episodes, nightmares, disturbed sleep, or other indications of undesirable central nervous system activity. Clomiphene which was the next most advanced in preclinical investigation or another of the structurally related antiestrogens could have been evaluated for anticancer activity in the early 1950s. However, the clinical evaluation of these compounds for those indications was never undertaken due to the concentration of effort on the use of clomiphene in induction of ovulation in anovulatory infertile women. In fact clomiphene citrate was later shown to have efficacy in breast cancer in a few patients in 1964(50). Resumption of investigation of similar antiestrogens for breast cancer had to wait for more than a decade. Chemists and biologists in the United Kingdom reexplored the triphenylethylenes for antiestrogenic and antifertility activity and eventually for antitumor activity. The clinical efficacy of one of these compounds, tamoxifen, established antiestrogens as the stand ard endocrine treatment in breast cancer. Development of Tamoxifen Tamoxifen (ICI 46,474; Nolvadex) (Fig. 1) is a nonsteroidal antiestrogen with antifertility properties in laboratory animals (51-54). The compound exhibits an interesting species-specific pharmacology (55); it is a pure antiestrogen in chicks (33) and 4181 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER an antiestrogen with partial estrogenic activity in rats (52) but, in short-term tests, it is classified as an estrogen in mice (51, 52, 56). However, it appears that the prolonged administration of tamoxifen to ovariectomized mice causes the uterus and vagina to become refractory to the stimulatory effects of estra dici (37, 57, 58). Tamoxifen is a competitive inhibitor of estradici binding to estrogen receptors (59, 60) and the compound inhibits the binding of estrogen to estrogen target tissues in vivo (57, 6164). Antiestrogens can inhibit estrogen-regulated events in cells in culture; e.g., tamoxifen slows the growth of MCF-7 breast cancer cells [in phenol red containing media (65, 66)]; however, the addition of increasing concentrations of estradiol will re verse the effects of tamoxifen and the cells will continue to grow ("estrogen rescue") (67). Nevertheless, high concentra tions of antiestrogens will cause estrogen irreversible actions (68, 69). An "antiestrogen binding site" has been described (70) but its relevance to the cytocidal actions of tamoxifen is not clear. It is clear, however, that the high affinity of tamoxifen to a variety of proteins causes ubiquitous binding of the drug in vivo and probably accounts for its long biological half-life Current research is focused on the action of growth factors to regulate the breast cancer cell cycle. Estrogens decrease cell cycle time and tamoxifen causes a reversible blockade at the G, phase (71, 72). Antiestrogens inhibit estrogen-stimulated in creases in transforming growth factor a, a stimulatory factor (73), and there is a complementary rise in transforming growth factor ÃŸ, an inhibitory growth factor (74). Although the actual regulatory mechanisms that orchestrate the inhibitory and stim ulatory actions of growth factors are unclear, this is an area of intense investigation. The knowledge that tamoxifen is an inhibitor of estrogen action focused attempts to develop an appropriate clinical ap plication. Tamoxifen was initially evaluated in a number of endocrine-responsive conditions (75-80) and the drug subse quently became available in some countries for the induction of ovulation in subfertile women. However, the discovery that the presence of the estrogen receptor may predict the hormone responsivness of advanced breast cancer (81) naturally led to the evaluation of tamoxifen to control tumor growth [tamoxifen inhibits the binding of estrogen to estrogen receptors derived from breast tumors (82)]. Much of the credit for steering the use of tamoxifen toward the treatment of advanced breast cancer must go to the late Dr. Arthur L. Walpole of ICI, Pharmaceuticals Division, Macclesfield, United Kingdom. Ear lier in his career Dr. Walpole had been particularly interested in carcinogenesis and cancer therapy but in the 1960s his attention was directed, as head of the fertility control program, to the development of antifertility agents (83). Much of the early preclinical antitumor work was subsequently conducted in my (V. C. J.) laboratory funded through the good offices of Arthur Walpole at ICI. Antitumor Actions of Tamoxifen in Laboratory Models The first systematic laboratory study of the antitumor action of tamoxifen was conducted at the Worcester Foundation for Experimental Biology in Shrewsbury, MA (82, 84-88). One of the results of this research (89, 90) was to encourage the clinical evaluation of tamoxifen in the United States by the Eastern Cooperative Oncology Group. Most of the early research on tamoxifen used carcinogeninduced rat mammary tumor models (85-90) but during the past half-decade interest has focused on an evaluation of the antitumor action of tamoxifen in athymic mice, heterotransplanted with breast cancer cell lines (91-95). Carcinogen-induced Models. Mammary tumors can be in duced in 50-day-old Sprague-Dawley rats by a single feeding (20 mg in 2 ml peanut oil) of DMBA. Tamoxifen will inhibit the initiation (85, 87) and growth (61, 88, 96-98) of DMBA2induced tumors. The model system could be likened to the treatment of advanced breast cancer but the tumors do not metastasize and therefore a direct analogy with breast cancer is impossible. This fact is important inasmuch as the fashion for the treatment of breast cancer was changing in the mid-1970s. A strategy was devised to use adjuvant hormonochemotherapy to destroy micrometastases following mastectomy, a treatment aimed at curing a majority of patients. Unfortunately no animal model system was, or is, available to duplicate the clinical situation to test the value of this treatment strategy in the laboratory. Nevertheless the DMBA- and yV-methylnitrosoureainduced rat mammary carcinoma models were adapted to eval uate whether antiestrogens could "cure" animals with a micro scope tumor burden. When DMBA is administered to Sprague-Dawley rats, the initiated mammary cells are promoted by circulating hormones to effect transformation. Palpable tumors appear 100-150 days after DMBA. There is therefore a period when microscopic disease can be treated to establish whether it is possible to cure the animals with antiestrogens. If different doses are adminis tered for 4 weeks starting at different times after DMBA (99, 100), a delay occurs in the appearance of tumors. In contrast continuous therapy causes the majority of animals to remain tumor free (101-103). Nevertheless of tamoxifen therapy is stopped, tumor growth recurs (104). A similar situation occurs with the carcinogen jV-methylnitrosourea; a short course of tamoxifen delays the appearance of tumors but the animals remain tumor free during a contin uous treatment regimen (105, 106). Athymic Mouse Models. Breast cancer cell lines can be heterotransplanted into athymic immunodeficient mice. Estradiol encourages the growth of hormone-responsive lines (e.g., MCF7) but hormone nonresponsive lines (e.g., MDA-MB-231) will grow with or without estrogen treatment. Tamoxifen and its metabolites inhibit estrogen-stimulated growth of estrogen re ceptor-positive tumors but in general do not inhibit the growth of receptor-negative tumors (91, 92). However, this model has been used successfully to determine whether tamoxifen pro duces a tumoristatic or tumoricidal effect on implanted hor mone-responsive breast cancer cells. If animals are treated for 1, 2, or 6 months with sustained release preparations of tamox ifen the tumor cells are not specifically destroyed. When the animals are treated with estradiol to identify surviving tumor cells, tumors regrow in every case (92, 93). Overall the experimental evidence points to the fact that tamoxifen is a tumoristatic rather than a tumoricidal agent. Long-term adjuvant tamoxifen treatment, or treatment until relapse, is predicted to be the best therapeutic strategy to control the recurrence of breast cancer following mastectomy. This application of tamoxifen can be called chemosuppression. Long-Term Adjuvant Tamoxifen Therapy Despite the developing laboratory data that demonstrated that tamoxifen is a tumoristatic agent (99-102), the vast ma2The abbreviation used is: DMBA, dimethylbenzanthracene. 4182 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER jority of clinical trials initially evaluated 1 or 2 years of adjuvant tamoxifen therapy. There were several sound reasons for this: (a) a short course of tamoxifen might produce a tumoricidal effect before the onset of resistance since it was known that patients with advanced disease respond to tamoxifen for only 1-2 years; (b) the adjuvant use of tamoxifen might encourage the early outgrowth of receptor-negative disease (the rationale was that it would be wiser to save the drug until recurrence so that physicians would have something available to treat the patient); and (c) the long-term side effects of tamoxifen were unknown (thousands of women with advanced disease had been treated, but only until relapse, 1-2 years later). Although tamoxifen was initially used conservatively the recent overview of all randomized clinical trials (107) has demonstrated the survival advantage of postmenopausal, nodepositive women who received 1 or 2 years of adjuvant tamoxifen therapy. Swayed by the encouraging clinical trial results and the laboratory findings (101, 107) clinical trials are currently focused on an evaluation of 5, 10, or in some cases indefinite adjuvant tamoxifen therapy in pre- and postmenopausal pa tients with node-positive and node-negative disease. In 1977, on the basis of encouraging laboratory data (101), Dr. Douglass C. Tormey organized a pilot nonrandomized adjuvant clinical study to identify any unusual side effects produced by long-term adjuvant tamoxifen therapy (5 years) and to evaluate the potential efficacy of the treatment strategy (108). The results demonstrated the safety of tamoxifen and provided promising preliminary data to establish the Eastern Cooperative Oncology Group protocols EST 4181 and EST 5181 to evaluate chemotherapy and different lengths of tamox ifen therapy in randomized clinical trials (109). The National Surgical Adjuvant Breast and Bowel Project has chosen a similar course of action. Based upon their suc cessful evaluation of 2 years of adjuvant tamoxifen and chemo therapy (110) they conducted a registration study of chemo therapy and tamoxifen for 2 years followed by an additional year of tamoxifen for those patients who did not have recur rence. The results are encouraging and support the view that long-term tamoxifen therapy benefits the patient (111). Several clinical trials have also evaluated the efficacy of longterm adjuvant tamoxifen therapy alone. A French study (112) has compared 3 years of adjuvant tamoxifen therapy versus no treatment. Tamoxifen produced a survival advantage especially in receptor-positive patients. Similarly a large clinical trial in Scotland (113) has evaluated whether it is an advantage to treat patients for 5 years with adjuvant tamoxifen. This clinical study is particularly interesting because it addresses the question of whether to use tamoxifen as an adjuvant therapy or to use the drug only when the patient develops advanced disease. In the Scottish study, patients in the control arm received tamoxifen at first recurrence. The results demonstrate that long-term adjuvant therapy with tamoxifen provides an effective control of disease recurrence and a survival advantage for the patient. There appears to be no need to delay the drug until recurrence because early drug resistance does not develop. The National Surgical Adjuvant Breast and Bowel Project is currently conducting a trial of long-term adjuvant tamoxifen therapy (10 years) in pre- and postmenopausal patients with node-negative estrogen receptor-positive disease. The prelimi nary results are again encouraging (114) inasmuch as tamoxifen-treated women have an extended disease-free survival. Overall the clinical trials community has demonstrated some advantages for long-term adjuvant tamoxifen therapy. To date the trial population has been diverse with both pre- and post menopausal women receiving tamoxifen alone and women with node-negative disease who might be treated for decades. This expanded and extended use of tamoxifen requires an ongoing evaluation of the pharmacology and potential toxicological consequences of indefinite therapy. Obviously it is important to establish the safety of tamoxifen to reassure both physicians and patients and to avoid unwarranted restrictions on this valuable chemosuppressive therapy. Clinical Pharmacology The clinical pharmacology of tamoxifen was initially inves tigated in patients with advanced breast cancer (115-118). The drug is readily absorbed following p.o. administration and accumulates to steady-state levels by the end of the first month of treatment (116). The serum levels of tamoxifen at steady state are extremely variable (50-300 ng/ml) but blood levels are not related to response (119). The principal metabolite of tamoxifen is ,/V-desmethyltamoxifen which produces blood lev els approximately twice as high as those of tamoxifen by the end of the first month of treatment. The serum half-lives of tamoxifen and W-desmethyltamoxifen are extremely long (7 and 14 days, respectively) (120), probably because the com pounds are highly protein bound. Tamoxifen is extensively metabolized in patients (121, 122) (Fig. 4) but to date no significant quantities of estrogenic metabolites have been noted that would cause concern during long-term adjuvant tamoxifen therapy. ,/V-Desmethyltamoxifen is further metabolized to metabolite Y which has a glycol side chain (123, 124). Tamoxifen is also converted to 4-hydroxytamoxifen but this is observed only at low concentrations in serum (118). However, this metabolite has an extremely high binding affinity for the estrogen receptor (the same as that of estradici) (125); therefore it probably plays a significant role in supporting the antitumor action of tamoxifen. Recently 4hydroxy-yV-desmethyltamoxifen has been identified in patients (126). This metabolite has been shown in the laboratory to be N-DESMETHYLTAMOXIFEN N.N. DIDESMETHYLTAMOXIFEN 4-HYDROXY N-DESMETHYL TAMOXIFEN METABOLITE Y Fig. 4. Metabolites of tamoxifen identified in patients. 4183 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER formed from either 4-hydroxytamoxifen or jV-desmethyltarnoxifen(127). The blood levels of tamoxifen and its metabolites are stable for up to 10 years of adjuvant therapy and no metabolic toler ance seems to occur. This fact and the low incidence of reported side effects (121) makes tamoxifen an ideal long-term chemosuppressive agent for the adjuvant treatment of breast cancer. Potential Side Effects of Long-Term Adjuvant Tamoxifen Ther apy Tamoxifen therapy is being extended beyond a decade. Indeed node-negative patients with only a moderate risk of recurrence may in fact receive the drug indefinitely. This raises important questions about the potential long-term side effects of nonsteroidal antiestrogens (Table 1). Estrogen is important in prevention of the development of osteoporosis in women; therefore the long-term administration of an "antiestrogen" would seem to imply that women may become predisposed to osteoporosis. Similarly estrogen pro tects women from coronary heart disease by altering the circu lating levels of cholesterol. Again it would seem that the longterm administration of an "antiestrogen" might not be benefi cial. However, tamoxifen exhibits some estrogen-like effects that appear to have target site specificity (55). Tamoxifen is an antiestrogen in the rat uterus (52) but displays estrogen-like effects in bone (128, 129). There are only few clinical data (130, 131) to support these beneficial laboratory findings but tamox ifen is clearly not detrimental to bone in patients. The beneficial effects of nonsteroidal antiestrogens on serum cholesterol has been noted previously in animals (41) and tamoxifen has been shown to lower serum cholesterol (mainly, low density lipoprotein) in patients (132, 133). Obviously the beneficial estrogen-like effects of tamoxifen in some target sites may prove to be a disadvantage in others. Estrogens can cause an increase in thromboembolic disorders and estrogen replacement therapy has been associated with an increase in endometrial carcinoma. Tamoxifen does not, how ever, cause a significant increase in thromboembolic disorders when administered alone but there is a small decrease in antithrombin III during long-term adjuvant tamoxifen therapy (132, 134). The decrease (generally not more than 30%) is, however, not great enough to cause clinical concern. Neverthe less patients with a history of thromboembolic disease probably should not be treated with tamoxifen. There is very little information about the effects of tamoxifen on the human uterus although tamoxifen does have some efficacy for treating endometrial carcinoma (135). Nevertheless tamoxifen has been implicated (anecdotally) in the development of endometrial carcinoma (136). Realistically, however, there is little possibility that tamoxifen could control the growth of all endometrial tumors as only about 1 of 3 are hormone responsive. Interestingly enough there is one provocative labo ratory observation (137) that tamoxifen can encourage the growth of a human endometrial carcinoma in athymic mice. Indeed this effect appears to be tumor specific (138). If athymic mice are bitransplanted with the endometrial tumor EnCalOl and the breast tumor MCF-7 and treated with estrogen and tamoxifen, the endometrial tumor is stimulated to grow whereas Table 1 Potential side effects of long-term adjuvant tamoxifen therapy Antiestrogenic actions Estrogenic actions Reproductive Osteoporosis, coronary heart disease Clotting, uterine stimulation Ovarian, teratogenesis the growth of the breast tumor is controlled by tamoxifen. One large clinical trial (139) has shown that a similar phenomenon can occur during long-term adjuvant tamoxifen therapy; Le, second breast tumors are reduced but there is an increase in endometrial carcinoma. To date these data have not been con firmed by any other major clinical trials organization and it is important to state that adjuvant tamoxifen therapy should not be denied to a patient on the basis of this potential side effect. It should be obvious that tamoxifen is of proven benefit (107) for the treatment of breast cancer, a disease that is invariably fatal, and endometrial carcinoma, should it occur, has a good prognosis. Routine gynecological examination must be per formed to monitor the health and well-being of the patients during adjuvant tamoxifen therapy. Finally, since more and more premenopausal patients are receiving adjuvant tamoxifen therapy, it should be stressed that they are at risk for pregnancy and require counseling about barrier contraceptives. Short-term tamoxifen treatment causes an increase in ovarian estrogen synthesis (140) and premeno pausal patients on long-term adjuvant tamoxifen regimens (with or without chemotherapy) continue to menstruate and have elevated circulating ovarian steroid hormone levels (141, 142). It is currently not known what the long-term effects of tamox ifen on the ovary will be; this is a topic for future clinical investigation. Clearly the elevated levels of estrogen, a known tumor mitogen, might be able to impair the antitumor action of the antiestrogen. Tamoxifen is, however, an effective antitumor agent in premenopausal women with advanced disease (121). This clinical situation has been investigated in the athymic animal model, and similar high circulating levels of estradici (500-800 pg/ml) do not reverse the antitumor action of tamox ifen (50 ng/ml).3 However, compliance issues with tamoxifen will be very important in premenopausal patients during longterm adjuvant tamoxifen. Strategies to lower circulating estro gen like oophorectomy or the administration of luteinizing hormone-releasing hormone agonists during adjuvant tamoxi fen therapy should be evaluated in future clinical trials. New Antiestrogens A study of the structure-activity relationships of tamoxifen has provided an important insight into the mechanism of action of both estrogens and antiestrogens. Early work demonstrated that antiestrogens had a weak interaction with the estrogen receptor (59, 143) and it was widely believed that this property was essential to inhibit hormone action (144); i.e., an estrogen would bind tightly to the receptor and the resulting complex could initiate estrogen-dependent events whereas an antiestro gen would bind to the receptor to block the access of estrogen but the complex would "fall apart" before it could itself initiate estrogen action. The discovery of the pharmacological proper ties of monohydroxytamoxifen (4-hydroxytamoxifen) (125, 145) changed this view of antiestrogen action. 4-Hydroxytamoxifen has an affinity for the estrogen receptor similar to that of estradici but it is a potent inhibitor of estrogen action. Subsequent confirmation of this work (146, 147) and the avail ability of radiolabeled material for studies in vitro and in vivo (147-150) has established the drug as a standard laboratory biochemical. During the 1980s a number of assay systems in vitro were used to describe the structure-function relationships of anties3 Y. lino and V. C. Jordan, unpublished observation. 4184 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER trogens (151-157). These model systems are important as they provide information about the direct effects of ligands on the cell without metabolic transformation. In the future this knowl edge will undoubtedly dovetail with current research on the molecular biology of the estrogen receptor to understand the complex conformation changes that occur in the receptor pro tein to program cell replication. As a result of the successful use of tamoxifen to treat breast cancer, several new antiestrogens are now being evaluated in the laboratory and the clinic. The structures of several of the new compounds are shown in Fig. 5. The literature on new antiestrogens is increasing dramatically and interested readers should consult recent reviews (122, 158). One notable advance is the investigation of nonestrogenic antiestrogens for potential clinical applications. The discovery process appears to have gone full circle (MER-25 has few estrogenic properties) to find compounds without the estrogenlike properties of the triphenylethylenes. At present only one compound (ICI 164,384) is available for evaluation and it has demonstrated activity as an inhibitor of estradiol action both in vivo and in vitro (159-162). Interestingly the steroid also has the ability to inhibit tamoxifen-stimulated tumor growth in the laboratory (Ref. 94; Fig. 6). Various pure antiestrogens are currently being evaluated in the laboratory and some are undergoing toxicology testing. When (or if) any of these new compounds become available for clinical application, they may provide some additional clues about estrogen-regulated breast cancer growth. One question has been whether the antitumor activity of tamoxifen is related to its estrogenic or antiestrogenic properties (or neither?) This could soon be resolved. It is possible that pure antiestrogens could produce longer responses in advanced disease or be useful as a second line therapy after long-term adjuvant tamoxifen treatment. This presupposes that a significant proportion of patients who eventually fail tamox ifen therapy do so because of the estrogen-like properties of tamoxifen. Unfortunately the potential of pure antiestrogens to produce osteoporosis or early atherosclerosis may preclude their use as a front line long-term adjuvant therapy in nodenegative disease. TRIOXIFENE DROLOXIFENE TOREMIFENE '"ICH j),0C N (CMjljCH, ICI 164, 384 CH, Fig. 5. Structures of new antiestrogens that are being evaluated in the labo ratory and the clinics. O 111 K DC O D WEEKS Fig. 6. Effect of the nonestrogenic antiestrogen ICI 164,384 on tamoxifenstimulated growth of endometrial tumor EnCa 101 in the athymic mouse. Animals were treated with a sustained release preparation of tamoxifen (2-cm Silastic capsule) (D), a control capsule (O), or ICI 164,384, 1 mg/0.1 ml peanut oil s.c. 3 times weekly (â€¢)or tamoxifen plus ICI 164,384 (â€¢). Current and Future Uses of Antiestrogens In the 30 years since the first publication of the pharmaco logical properties of MER-25, the clinical application of antiestrogens has proved to be a remarkable success. Tamoxifen is now the antihormonal treatment of choice for advanced breast cancer (pre- and postmenopausal). As valuable as this applica tion is as a palliative treatment, the remarkable advances have undoubtedly been made in the application of antiestrogens to treat all stages of breast cancer. Tamoxifen is the antihormonal treatment of choice for the adjuvant therapy of postmenopausal node-positive women. Two years of treatment is known to produce a survival advantage, and longer treatment schedules are being evaluated to exploit the known tumoristatic qualities of tamoxifen. We already know that long-term adjuvant tamox ifen therapy (5 years) is beneficial compared to saving tamoxifen until first recurrence, so 10-year and indefinite schedules are being evaluated. The proven efficacy and low incidence of side effects have encouraged the evaluation of adjuvant tamoxifen therapy in pre- and postmenopausal women with node-negative disease. At present the long-term toxicological concerns appear to be negligible compared to the known course of breast cancer without treatment. Hundreds of thousands of women could be being treated indefinitely with tamoxifen by the turn of the century. Indeed it has even been suggested that antiestrogens could be used to prevent breast cancer. However, the timing and cause of the carcinogenic insult are unknown; therefore the use of antiestrogens as true preventives seems impractical. A better term, also applicable to adjuvant therapy, is chemosuppressive; i.e., the drug can be used to suppress subclinical disease and prevent the appearance of a primary tumor (163). In some adjuvant trials tamoxifen inhibits the development of second primary breast tumors (114, 139, 164) and an early clinical evaluation of the toxicology of tamoxifen in normal women has been reported (165) as a first step in a prevention study. Nevertheless there is a real concern about being able to target the right population. We cannot predict who will develop breast cancer; we can only guess at the probability. Furthermore "high risk" women are, in fact, only a minority of those who will develop breast cancer so any success must be balanced against as yet unknown accumulative toxicities. Is this the end of the possible applications for antiestrogens? Certainly not. We have obtained valuable clinical information 4185 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER about this group of drugs that can be applied in other disease states. Research does not travel in straight lines and observa tions in one field of science often become major discoveries in another. Important clues have been garnered about the effects of tamoxifen on bone and lipids so it is possible that derivatives could find targeted applications to retard osteoporosis or ath erosclerosis. The ubiquitous application of novel compounds to prevent diseases associated with the progressive changes after menopause may, as a side effect, significantly retard the devel opment of breast cancer. The target population would be postmenopausal women in general, thereby avoiding the require ment to select a high risk group to prevent breast cancer. 20. Acknowledgments 21. This paper is not intended to be an encyclopedic review article but is offered only as a personal recounting of research conducted in our respective laboratories during a period that has spanned almost 40 years. We sincerely acknowledge the support of colleagues, students, and assistants in our respective laboratories. We also acknowledge the important additional contributions made to the understanding of an tiestrogen action by James H. Clark, Kathryn B. Horwitz, Benita and John Katzenellenbogen, Marc E. Lippman, C. Kent Osborne, Robert I. Nicholson, Henri Rochefort, Robert L. Sutherland, and Alan E. Wakeling. The influence of our teachers the late James H. Leatham and the late James B. Allison (L. J. L.) and Edward R. Clark (V. C. J.) was important for the direction and development of our investigative approach. Dr. Lerner is ever grateful for the encouragement he received as a developing scientist from Roy O. Creep, Roy Hertz, the late Albert Segaloff, and the late Ralph Dorfman. Dr. Jordan wishes to acknowl edge William L. McGuire, Jack Gorski, Elwood V. Jensen, the late Arthur L. Walpole, and colleagues at ICI for their invaluable help and support and Paul P. Carbone, Richard R. Love, Bernard Fisher, Sydney E. Salmon, and Douglass C. Tormey for the clinical application of many of the concepts and results described here. The EnCalOl tumor was kindly provided by Dr. P. G. Satyaswaroop, Department of Ob stetrics and Gynecology, Hershey School of Medicine, Hershey, PA, for the experiment in Fig. 6 performed by Dr. Marco M. Gottardis and Michelle Ricchio. 22. 15. 16. 17. 18. 19. 23. 24. 25. 26. 27. 28. 29. 30. 31. References 1. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, 2: 104-107, 162-167, 1896. 2. Dao, T. L., and Muggins, C. Bilateral adrenalectomy in the treatment of cancer of the breast. A. M. A. Arch. Surg., 71: 645-657, 1955. 3. Pearson, O. H., and Ray, B. S. Results of treatment of metastatic mammary carcinoma. Cancer (Phila.), 12: 85-92, 1959. 4. Allen, E., and Doisy, E. A. The induction of a sexual mature condition in immature females by injection of the ovarian follicular hormone. Am. J. Physiol., 69: 577-588, 1924. 5. Cook, J. W., Dodds, E. C., and Hewett, C. L. A synthetic oestrus-exciting compound. Nature (Lond.), 131: 56-57, 1933. 6. Dodds, E. C., Golberg, L., Lawson, W., and Robinson, R. Oestrogenic activity of certain synthetic compounds. Nature (Lond.), 141: 247-248, 1938. 7. Dodds, E. C., Golberg, L., Lawson, W., and Robinson, R. Oestrogenic activity of alkalated stilboestrols. Nature (Lond.), Â¡42:34, 1938. 8. Robson, J. M., and Schonberg, A. Oestrous reactions, including mating, produced by triphenylethylene. Nature (Lond.), 140: 196, 1937. 9. Robson, J. M., and Schonberg, A. A new synthetic estrogen with prolonged action when given orally. Nature (Lond.), 150: 22-23, 1942. 10. Thompson, C. R., and Werner, H. W. Studies on estrogen tri-p-anisylchloroethylene. Proc. Soc. Exp. Biol. Med., 77: 494-497, 1951. 11. Shelton, R. S., VanCampen, M. G., Jr., Meisner, D. F., Parmeter, S. M., Andrews, E. R., Allen, R. E., and Wyckoff, K. K. Synthetic estrogens. Halotriphenyl ethylene derivatives. J. Am. Chem. Soc., 75: 5491-5493, 1953. 12. Robson, J. M. Quantitative data on the inhibition of oestrus by testosterone, progesterone and certain other compounds. J. Physiol., 92: 371-382, 1938. 13. Szego, C. M., and Roberts, S. Pituitary-adrenal antagonism to estrogenic stimulation of the uterus of the ovariectomized rat. Am. J. Physiol., 152: 131-140, 1948. 14. Velardo, J. T., Hisaw, F. L., and Bever, A. T. Inhibitory action of cortisone 32. 33. acetate, desoxycorticosterone acetate and testosterone on estradiol-17 in duced uterine growth. Endocrinology, 59: 165-169, 1956. Edgren, R. A., and Calhoun, D. W. Estrogen antagonisms: inhibition of estrone-induced uterine growth by testosterone propionate, progesterone and 17-ethyl-19-nortestosterone. Proc. Soc. Exp. Biol. Med., 94: 537-539, 1957. Lerner, L. J., Holthaus, F. J., Jr., and Thompson, C. R. A myotrophic agent and gonadotrophin inhibitor, 19-nortestosterone-17-benzoate. Endo crinology, 64: 1010-1016, 1959. Hisaw, F. L., Velardo, J. T., and Goolsby, C. M. Interaction of estrogens on uterine growth. J. Clin. Endocrino!., 14: 1134-1143, 1954. Velardo, J. T., and Sturgis, S. H. Interaction of 16-epi-estriol and estradiol17 on uterine growth. Proc. Soc. Exp. Biol. Med., 90: 609-610, 1955. Muggins, C., and Jensen, E. V. The depression of estrone-induced uterine growth by phenolic estrogens with oxygenated functions at position 6 or 16: the impeded estrogens. J. Exp. Med., 102: 335-346, 1955. Edgren, R. A., and Calhoun, D. W. Oestrogen antagonisms: the effects of oestriol and 16-epioestriol on oestrone-induced uterine growth in spayed rats. J. Endocrinol., 20: 325-330, 1960. Edgren, R. A., and Calhoun, D. W. Interaction of estrogens on the vaginal smear of spayed rats. Am. J. Physiol., 189: 355-357, 1957. Lerner, L. J. Uterotrophic and antiestrogenic activity of a non-steroidal compound in mice. In: Conference on Comparison of Biological Properties of Steroids and Hormones, Detroit 1954, Committee on Research, Council on Pharmacy and Chemistry, American Medical Association, pp. 115-117. Jensen, E. V., Jacobson, H. I., Flesher, J. W., Saha, N. N., Gupta, G. N., Smith, S., Colucci, V., Shiplacoff, D., Neumann, H. G., DeSombre, E. R., and Junglut, P. W. Estrogen receptors in target tissues. In: T. Nakao, G. Pincus, and J. Tait (eds.), Steroid Dynamics, pp. 133-157. New York: Academic Press, 1966. Jensen, E. V., Numata, M., Smith, S., Suuki, T., Brecker, P. I., and DeSombre, E. R. Estrogen-receptor interaction in target tissues. Dev. Biol., Suppl. 3, 151-171, 1969. Lerner, L. J. Estrogen antagonistic activity of l-(/7-2-diethylaminoethoxyphenyl)-l-phenyl-2-/>-anisylethanol (MER-25). Fed. Proc., 17: 388, 1958. Lerner, L. J., Holthaus, F. J., Jr., and Thompson, C. R. A non-steroidal estrogen antagonist l-(/)-2-diethylaminoethoxyphenyl)-l-phenyl-2-^-methoxyphenyl ethanol. Endocrinology, 63: 295-318, 1958. Lerner, L. J. Hormone antagonists: inhibitor of specific activities of estrogen and androgen. Recent Prog. Horm. Res., 20: 435-490, 1964. Lerner, L. J. Steroid hormones and uterine growth. Ann. NY Acad. Sci., 75:460-462, 1959. Lerner, L. J., Hilf, R., Turkheimer. A. R., Michel, I., and Engel, S. L. Effects of hormone antagonists on morphological and biochemical changes induced by hormonal steroids in the rat uterus. Endocrinology, 78: 111124, 1966. Lerner, L. J., Harris, D. N., Hilf, R., Bianchi, A., and Raskin, B. K. Responses of the rat uterus and oviduct to sex steroids as influenced by time and antagonists. In: Proceedings of the Second International Congress on Hormonal Steroids, Milan, 1966. Excerpta Medica International Congress Series No. 132, Amsterdam, pp. 628-638. Amsterdam: Excerpta Medica, 1967. Harris, D. N., Lerner, L. J., and Hilf, R. The effects of progesterone and ethamoxytriphetol on estradiol-induced changes in the immature rat uterus. Trans. NY Acad. Sci., 30: 774-782, 1968. Lerner, L. J., Hilf, R., and Harris, D. N. The effect of antagonists on androgen- and estrogen-induced changes in the male accessory sex organs of the rat. Trans. NY Acad. Sci., 30: 783-793, 1968. Sutherland, R. L., Mester, J., and Baulieu, E. E. Tamoxifen is a potent "pure" antioestrogen in the chick oviduct. Nature (Lond.), 267: 434-435, 1977. 34. Sutherland, R. L. Estrogen antagonists in chick oviduct: antagonist activity of eight synthetic triphenylethylene derivatives and their interactions with cytoplasmic and nuclear estrogen receptors. Endocrinology, 109: 20612068, 1981. 35. Segal, S. J., and Nelson, W. O. An orally active compound with antifertility effects in rats. Proc. Soc. Exp. Biol. Med., 98: 431-436, 1958. 36. Chang, M. C. Degeneration of ova in the rat and rabbit following oral administration of l-(p-2-diethylaminoethoxyphenyl)-l-phenyl-2-/j-anisylethanol. Endocrinology, 65: 339-342, 1959. 37. Emmens, C. W. Compounds exhibiting prolonged antiestrogenic and antifertility activity in mice and rats. J. Reprod. FÃ©rtil.,26: 175-182, 1971. 38. Clark, E. R., and Jordan, V. C. Oestrogenic, anti-oestrogenic and fertility properties of a series of compounds related to ethamoxytriphetol (MER25). Br. J. Pharmacol., 57:487-493, 1976. 39. Morris, J. M., VanWagenen, G., McCann, J., and Jacobs, D. Compounds interfering with ovum implantation and development. II. Synthetic estrogens and antiestrogens. FÃ©rtil.Steril., 18: 18-34, 1967. 40. Kamboj, V. P., Setty, B. S., Chandra, H., Roy, S. K., and Kar, A. B. Biological profile of centchromanâ€”a new post-coital contraceptive. Ind. J. Exp. Biol., /5: 1144-1146, 1977. 41. Lerner, L. J. The first non-steroidal antioestrogen-MER-25. In: R. L. Sutherland and V. C. Jordan (eds.), Non-steroidal antioestrogens: Molecular Pharmacology and Antitumor Activity, pp. 1-16. Sydney, Australia: Aca demic Press, 1981. 42. Adams, W. C., France, E. S., and Leathern, J. H. The influence of an estrogen antagonist on reproductive physiology in the female rat. Proc. Pa. Acad. Sci., 34: 155-158, 1960. 4186 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER 43. Leathern, J. H., and Adams, W. C. Prevention of ovarian cyst formation by ethamoxytriphetol (MER-25). Proc. Soe. Exp. Biol. Med., 113: 240-242, 1963. 44. Kistner, R. W., and Smith, O. W. Observations on the use of a non-steroidal estrogen antagonist: Mer-25. Surg. Forum, 10: 725-729, 1960. 45. Kistner, R. W., and Smith, O. W. Observations on the use of a nonsteroidal estrogen antagonist: Mer-25. II. Effects in endometrial hyperplasia and Stein-Leventhal syndrome. FÃ©rtil.Steril., 12: 121-141, 1961. 46. Tyler, E. T., Olson, H. J., and Gotlib, M. H. The induction of ovulation with an anti-estrogen. Int. J. FÃ©rtil.,5:429-436, 1960. 47. Holtkamp, D. E., Greslin, J. G., Root, C. A., and Lerner, L. J. Gonadotrophin inhibiting and anti-fecudity effects of chloramiphene. Proc. Soc. Exp. Biol. Med., 705: 197-201, 1960. 48. Greenblatt, R. B., Barfield, W. E., Jungck, E. C., and Ray, A. W. Induction of ovulation with MRL-41. Preliminary report. JAMA, 178:101-104,1961. 49. Lerner, L. J., Harris, D. N., Yiacas, E., Hilf, R., and Michel, I. Cholesterol synthesis inhibitor showing reduction of lipids and hormone antagonism. Am. J. Clin. Nutr., 23: 1241-1250, 1970. 50. Herbst, A. L., Griffiths, C. T., and Kistner, R. W. Clomiphene citrate (NSC35770) in disseminated mammary carcinoma. Cancer Chemother. Rep., 43: 39-41, 1964. 51. Harper, M. J. K., and Walpole, A. L. Contrasting endocrine activities of m and trans isomers in a series of substituted triphenylethylenes. Nature (Lond.), 2/2:87, 1966. 52. Harper, M. J. K., and Walpole, A. L. A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J. Reprod. FÃ©rtil.,13: 101-119, 1967. 53. Harper, M. J. K., and Walpole, A. L. Mode of action of ICI 46,474 in preventing implantation in rats. J. Endocrinol., 37: 83-92, 1967. 54. Labhsetwar, A. P. Role of estrogens in ovulation. A study using the estrogen antagonist ICI 46,474. Endocrinology, 87: 542-551, 1970. 55. Jordan, V. C., and Robinson, S. P. Species-specific pharmacology of antiestrogens: role of metabolism. Fed. Proc., 46: 1870-1874, 1987. 56. Terenius, L. Structure-activity relationships of anti-oestrogens with regard to interaction with 17ÃŸ-oestradiolin the mouse uterus and vagina. Acta Endocrinol. Copenh., 66: 431-447, 1971. 57. Jordan, V. C. Prolonged antioestrogenic activity of ICI 46,474 in the ovariectomized mouse. J. Reprod. FÃ©rtil.,52: 251-258, 1975. 58. Jordan, V. C., Lababidi, M. K., and Mirecki, D. M. Inhibition of mouse mammary tumorigenesis by the antiestrogen tamoxifen. In: Proceedings of the British Pharmacological Society, King College, London, Abstract 22, December 1988. 59. Skidmore, J. R., Walpole, A. L., and Woodburn, J. Effect of some triphen ylethylenes on oestradiol binding in vitro to macromolecules from uterus and anterior pituitary. J. Endocrinol., 52: 289-298, 1972. 60. Jordan, V. C., and Prestwich, G. Binding of [3H] tamoxifen in rat uterine cytosols. A comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis. Mol. Cell. Endocrinol., 8: 179-188, 1977. 61. Jordan, V. C., and Dowse, L. J. Tamoxifen as an antitumour agent: effect on oestrogen binding. J. Endocrinol., 68: 297-303, 1976. 62. Jordan, V. C., Dix, C. J., Rowsby, L., and Prestwich, G. Studies on the mechanisms of action of the non-steroidal antioestrogen (ICI 46,474) in the rat. Mol. Cell. Endocrinol., 7: 177-192, 1977. 63. Jordan, V. C., Rowsby, L., Dix, C. J., and Prestwich, G. Dose-related effect of non-steroidal antioestrogens and non-steroidal oestrogens on the meas urement of cytoplasmic oestrogen receptors in the rat and mouse uterus. J. Endocrinol., 78: 71-81, 1978. 64. Jordan, V. C., and Naylor, K. E. Binding of [3H]oestradiol in the immature rat uterus during the sequential administration of antioestrogens. Br. J. Pharmacol., 65: 167-173, 1979. 65. Berthois, Y., Katzenellenbogen, J. A., and Katzenellenbogen, B. S. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Nati. Acad. Sci, USA, Â«5:2496-2500, 1986. 66. Bindal, R. D., Carlson, K. E., Katzenellenbogen, B. S., and Katzenellenbo gen, J. A. Lipophilic impurities, not phenosulfophthalein, account for the estrogenic activity in commercial preparations of phenol red. J. Steroid Biochem., 31: 287-293, 1988. 67. Lippman, M. E., and BolÃ¡n,G. Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond.), 256: 592-595, 1975. 68. Reddel, R. R., Murphy, L. C., and Sutherland, R. L. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res., 43: 4618-4614, 1983. 69. Taylor, C. M., Blanchard, B., and Zava, D. T. Estrogen receptor mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen. Cancer Res., 44: 1409-1414,1984. 70. Sutherland, R. L., Murphy, L. C., Foo, M. S., Green, M. D., Wybourne, A. M., and Krozowski, Z. S. High affinity antioestrogen binding site distinct from the oestrogen receptor. Nature (Lond.), 288: 273-275, 1980. 71. Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. R., and Taylor, I. W. Tamoxifen induces accumulation of MCF-7 human mammary carci noma cells in the Go/G] phase of the cell cycle. Eur. J. Cancer Clin. OncoL, 19: 615-621, 1983. 72. Osborne, C. K., Boldt, D. H., Clark, G. M., and Trent, J. M. Effect of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G, phase. Cancer Res., 43: 3583-3586, 1983. 73. Bates, S. E., Davidson, N. E., Vilverius, E. M., FrÃ©ter,C. E., Dickson, R. B., Tarn, J. P., Kudlow, J. E., Lippman, M. E., and Salomon, D. S. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100. 101. 102. 103. 104. Expression of transforming growth factor a and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrino!., 2: 543-555, 1988. Knabbe, C., Lippman, M. E., Wakefield, L. M., Flanders, K. C., Kasid, A., Derynck, R., and Dickson, R. B. Evidence that transforming growth factor ÃŸis a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48: 417-428, 1987. Cole, M. P., Jones, C. T. A., and Todd, I. D. H. A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46,474, Br. J. Cancer, 25: 270-275, 1971. Ward, H. W. C. Antioestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J., /: 13-14, 1973. O'Halloran, M. J., and Maddock, P. G. ICI 46,474 in breast cancer. J. Ir. Med. Assoc., 67: 38-39, 1974. Klopper, A., and Hall, M. New synthetic agent for the induction of ovula tion. Preliminary trial in women. Br. Med. J., /: 152-154, 1971. El-Sheikha, Z., Klopper, A., and Beck, J. S. Treatment of menometrorrhagia with antioestrogen. Clin. Endocrinol., /: 275-282, 1972. Williamson, J. G., and Ellis, J. D. The induction of ovulation by tamoxifen. J. Obstet. Gynaecol. Br. Commonw., 80: 844-847, 1973. Jensen, E. V., Block, G. E., Smith, S., Kyser, K., and DeSombre, E. R. Estrogen receptors and breast cancer response to adrenalectomy. Nati. Cancer Inst. Monogr., 34: 55-70, 1971. Jordan, V. C., and Koerner, S. Tamoxifen (ICI 46,474) and the human carcinoma 8S estrogen receptor. Eur. J. Cancer, 11: 205-206, 1975. Jordan, V. C. The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole. Breast Cancer Res. Treat., 11: 197209, 1988. Investigational Drug Brochure for ICI 46,474. Clinical Research Depart ment, ICI Americas Inc., Wilmington, DE, March 1974. Jordan, V. C. Antitumour activity of the antioestrogen ICI 46,474 (tamox ifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carci noma model. J. Steroid. Biochem., 5: 354, 1974. Jordan, V. C., Koerner, S., and Robison, C. Inhibition of oestrogen-stimu lated prolactin release by antioestrogens. J. Endocrinol., 65:151-152,1975. Jordan, V. C. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12: 419-424, 1976. Jordan, V. C., and Koerner, S. Tamoxifen as an antitumour agent: role of oestradiol and prolactin. J. Endocrinol., 68: 305-310, 1976. Jordan, V. C. The antiestrogen tamoxifen (ICI 46,474) as an antitumor agent. Proceedings of the Eastern Cooperative Oncology Group, Miami, FL, February 11-12, 1974. Jordan, V. C. Tamoxifen: mechanism of antitumor activity in animals and man. Proceedings of the Eastern Cooperative Oncology Group, Jaspar, Alberta, Canada, June 22-25, 1974. Osborne, C. K., Hobbs, K., and Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic mice. Cancer Res., 45: 584-590, 1985. Gottardis, M. M., Robinson, S. P., and Jordan, V. C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J. Steroid. Biochem., 30: 311-314, 1988. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988. Gottardis, M. M., Jiang, S. Y., Jeng, M. H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49:4090-4093, 1989. Jordan, V. C., Gottardis, M. M., Robinson, S. P., and Friedl, A. Immunedeficient animals to study "hormone-dependent" breast and endometrial cancer. J. Steroid. Biochem., 34: 169-176, 1989. Jordan, V. C. The antitumour affect of tamoxifen in the dimethylbenzanthracene-induced mammary carcinoma model. Proceedings of a Symposium on the Hormonal Control of Breast Cancer, Alderley Park, pp. 11-17. Macclesfield, United Kingdom: ICI Pharmaceuticals Division PLC, 1975. Nicholson, R. I., and Golder, M. P. Effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur. J. Cancer, //: 571-579, 1975. Jordan, V. C., and Jaspan, T. Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J. Endocrinol., 68: 453460, 1976. Jordan, V. C., Dix, C. J., and Allen, K. E. The effectiveness of long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In: S. E. Salmon and S. E. Jones (eds.), Adjuvant Therapy for Cancer II, pp. 19-26. New York: GruÃ±eand Stratton, 1979. Jordan, V. C., and Allen, K. E. Evaluation of the antitumor activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur. J. Cancer, 16: 239-251, 1980. Jordan, V. C. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. Rev. Endocrinol. Rei. Cancer, October Suppl., 49-55, 1978. Jordan, V. C., Allen, K. E., and Dix, C. J. The pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep., 64: 745-759, 1980. Robinson, S. P., and Jordan, V. C. Reversal of the antitumor effect of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res., 47: 5386-5390, 1987. Robinson, S. P., Mauel, D. A., and Jordan, V. C. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mam- 4187 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER mary tumor model. Eur. J. Cancer Clin. Oncol., 24: 1817-1821, 1988. 105. Wilson, A. J., Tehrani, F., and Baum, M. Adjuvant tamoxifen therapy for early breast cancer: an experimental study with reference to oestrogen and progesterone receptors. Br. J. Surg., 69: 121-125, 1982. 106. Gottardis, M. M, and Jordan, V. C. The antitumor actions of keoxifene and tamoxifen in the A'-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47: 4020-4024, 1987. 107. Early Breast Cancer Trialists' Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N. Engl. J. Med., 319: 1681-1692, 1988. 108. Tormey, D. C., and Jordan, V. C. Long-term tamoxifen adjuvant therapy in node positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res. Treat., 4: 297-302, 1984. 109. Falkson, H. C., Gray, R., and Wolberg, W. M. Adjuvant therapy of postmenopausa! women with breast cancerâ€”an ECOG phase III study. Abstract 67. Proc. ASCO San Francisco May, 1989. 110. Fisher, B., Redmond, C., Brown, A., Fisher, E. R., Wolmark, N., Bowman, D., Plotkin, D., Wolter, J., Bornstein, R., Legault-Poisson, S., Saffer, E. A., and Other NSABP Investigators. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5 year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J. Clin. Oncol., 4: 459-471, 1986. 111. Fisher, B., Brown, A., Wolmark, N., Redmond, C, Wickerham, L., Wittliff, J., Dimitrov, N., Legault-Poisson, S., Schipper, H., Prager, D., and Other NSABP Investigators. Prolonging tamoxifen therapy for primary breast cancer. Ann. Intern. Med., Â¡06:649-654, 1987. 112. Delozier, T., Julien, J-P., Juret, P., Veyret, C., Couette, J-E., Grai, Y., Olliver, J-.M.. and de Ranier, E. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res. Treat., 7: 105-110, 1986. 113. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC). Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Lancet, 2: 171-175, 1987. 114. Fisher, B., Constantino, J., Redmond, C., and Other Members of the NSABP. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptorpositive tumors. N. Engl. J. Med., 320: 479-484, 1989. 115. Fromson, J. M., Pearson, S., and Bramali. S. The metabolism of tamoxifen (ICI 46,474) Part II in female patients. Xenobiotica, 3: 711-713, 1973. 116. Fabian, C., Sternson, L., and Barrett, M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat. Rep., 64: 765-773, 1980. 117. Adam, H. K., Gay, M. A., and Moore, R. H. Measurement of tamoxifen in serum by thin layer densitometry. J. Endocrinol., 84: 35-42, 1982. 118. Daniel, C. P., Gaskell, S. J., Bishop, H., and Nicholson, R. I. Determination of tamoxifen and a hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J. Endocrinol., 83: 401 -408, 1979. 119. Bratherton, D. G., Brown, C. H., Buchanan, R., Hall, V., Kinglsey Pillers, E. M., Wheeler, T. K., and Williams, C. J. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br. J. Cancer, 50: 199-205, 1984. 120. Patterson, J. S., Settatree, R. S., Adam, H. K., and Kemp, J. V. Serum concentrations of tamoxifen and major metabolites during long-term Nol vadex therapy, correlated with clinical response. In: H. T. Mouridsen and T. Palshoff (eds.). Breast Cancerâ€”Experimental and Clinical Aspects, pp. 89-92. Oxford, United Kingdom: Pergamon Press, 1980. 121. Furr, B. J. A., and Jordan, V. C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther., 25: 127-205, 1984. 122. Robinson, S. P., and Jordan, V. C. The metabolism of steroid modifying anticancer agents. Pharmacol. Ther., 36: 41-103, 1988. 123. Jordan, V. C., Bain, R. R., Brown, R. R., Gosden, B., and Santos, M. A. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. Cancer Res., 43: 1446-1450, 1983. 124. Kemp, J. V., Adam, H. K., Wakeling, A. E., and Slater, R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem. Pharmacol., 32: 2045-2052, 1983. 125. Jordan, V. C., Collins, M. M., Rowsby, L., and Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol., 75: 305-316, 1977. 126. Lein, E. A., Solheim, E., Kvinnsland, S., and Veland, P. M. Identification of 4-hydroxy W-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res., 48: 2304-2308, 1988. 127. Robinson, S. P., Langan-Fahey, S. M., and Jordan, V. C. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol., 25: 1769-1776, 1989. 128. Jordan, V. C., Phelps, E., and Lingren, J. U. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat., 10: 3135, 1987. 129. Turner, R. T., Wakely, G. K., Hannon, K. S., and Bell, N. H. Tamoxifen prevents the skeletal effects of ovarian deficiency in rats. J. Bone Miner. Res., 2:449-456, 1987. 130. Love, R. R., Mazess, R. B., Tormey, D. C., Barden, H. S., Newcomb, P. A., and Jordan, V. C. Bone mineral density in women with breast cancer treated for at least two years with tamoxifen. Breast Cancer Res. Treat., 12: 297-301, 1988. 131. TÃ¼rken,S., Siris, E., Seidin, E., Seidin, D., Plaster, E., Hyman, G., and Lindsay, R. Effects of tamoxifen on spinal bone density in women with breast cancer. J. Nati. Cancer Inst., */: 1086-1088, 1989. 132. Bertelli, G., Pronzoto, P., and Amoroso, D. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III. Breast Cancer Res. Treat., 12: 307-310, 1988. 133. Love, R. R., Newcomb, P. A., Wiebe, D. A., Surawicz, T. S., Jordan, V. C., Carbone, P. P., and DeMets, D. C. Lipids and lipoprotein effects of tamoxifen therapy in postmenopausal women with node negative breast cancer. Breast Cancer Res. Treat., 13: Abstract 204, 1989. 134. Jordan, V. C., Fritz, N. F., and Tormey, D. C. Long-term adjuvant therapy with tamoxifen effects on sex hormone binding globulin and antithrombin III. Cancer Res., 47: 4517-4519, 1987. 135. Swenerton, K. D. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat. Rep., 64: 805-811, 1980. 136. Killackey, M. A., Hakes, T. B., and Pierce, V. K. Endometrial adenocarci noma in breast cancer patients receiving tamoxifen. Cancer Treat. Rep., 69: 237-238, 1985. 137. Satyaswaroop, P. G., Zaino, R. J., and Mortel, R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res., 44: 4006-4010, 1984. 138. Gottardis, M. M., Robinson, S. P., Satyaswaroop, P. G., and Jordan, V. C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res., 48: 812-815, 1988. 139. Fornander, T., Rutquist, L. E., Cedermark, B., Glas, U., Mattson, A., Siljversward, J. D., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., and Hjolmar, M. L. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet, 1: 117-120, 1989. 140. Groom, G. V., and Griffiths, K. Effect of the antioestrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J. En docrinol., 70:421-428, 1976. 141. Jordan, V. C., Fritz, N. F., and Tormey, D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node positive patients with breast cancer. Cancer Res., 47: 624-630, 1987. 142. Ravdin, P. M., Fritz, N. F., Tormey, D. C., and Jordan, V. C. Endocrine status of premenopausal node positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res., 48: 10261029, 1988. 143. Korenman, S. G. Relation between estrogen inhibiting activity and binding to cytosol of rabbit and human uterus. Endocrinology, 87:1119-1123,1970. 144. Bouton, M. M., and Raynaud, J. P. The relevance of interaction kinetics in determining biological response to estrogens. Endocrinology, 705:509-575, 1979. 145. Jordan, V. C., Dix, C. J., Naylor, K. E., Prestwich, G., and Rowsby, L. Nonsteroidal antiestrogens: their biological effects and potential mecha nisms of action. J. Toxicol. Environ. Health, 4: 364-390, 1978. 146. Binan. N., Catelli, M. H., Geynet, Puri, V., Hahnel, R., Mester, J., and Baulieu, E. E. Monohydroxytamoxifen: an antiestrogen with high affinity for the chick oviduct oestrogen receptor. Biochem. Biophys. Res. Commun., 91: 812-818, 1979. 147. Borgna, J. L., and Rochefort, H. High affinity binding to the estrogen receptor of [3H] 4-hydroxytamoxifen, an active antiestrogen metabolite. Mol. Cell. Endocrinol., 20: 71-85, 1980. 148. Rochefort, H., and Borgna, J. L. Differences between oestrogen receptor activated by oestrogen and antioestrogen. Nature (Lond.), 292: 257-259, 1981. 149. Jordan, V. C., and Bowser-Finn, R. A. Binding of [3H] monohydroxytamoxifen by immature rat tissues in vivo. Endocrinology, 110: 1281-1291, 1982. 150. Tate, A. C., Greene, G. L., DeSombre, E. R., Jensen, E. V., and Jordan, V. C. Differences between estrogen and antiestrogen-estrogen receptor com plexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res., 44: 1012-1018, 1984. 151. Lieberman, M. E., Gorski, J., and Jordan, V. C. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J. Biol. Chem., 258: 4741-4745, 1983. 152. Jordan, V. C., Lieberman, M. E., Cormier, E., Bagely, J., and Ruenitz, P. Structural requirements for the pharmacological activity of non-steroidal antiestrogens in vitro. Mol. Pharmacol., 26: 272-278, 1984. 153. Jordan, V. C., and Lieberman, M. E. Estrogen-stimulated prolactin synthe sis /'/; vitro: classification of agonist, partial agonist and antagonist actions based on structure. Mol. Pharmacol., 26: 279-285, 1984. 154. Jordan, V. C., Koch, R., Mittal, S., and Schneider, M. R. Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br. J. Pharmacol., 87: 217-220, 1986. 155. Jordan, V. C., Koch, R., Langan, S., and McCague, R. Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. Endocrinology, 122: 1449-1454, 1988. 156. Bignon, E., Pons, M., Crastes de Paulet, A., Dore, J. C., Gilbert, J., Abecassis, J., Miquel, J. F., Ojasoo, T., and Raynaud, J. P. Effect of triphenylacrylonitrile derivatives on estradiol-receptor binding and on hu man breast cancer cell growth. J. Med. Chem., 32: 2092-2103, 1989. 157. Murphy, C. S., and Jordan, V. C. Structural components necessary for the antiestrogenic activity of tamoxifen. J. Steroid Biochem., 34: 407-411, 1989. 158. Jordan, V. C. Biochemical pharmacology of antiestrogen action. Pharmacol. Rev., 36: 245-276, 1984. 4188 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. ANTIESTROGENS AND BREAST CANCER 159. Wakeling, A. E., and Bowler, J. Steroidal pure antioestrogens. J. Endocrinoi //2-R7-R10 1987 160. Cormier, E. M., and Jordan, V. C. Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor. ,?-,â€¢r. ir 57-63, t--, f-, ,oon Eur. J., ^Cancer Clin. Oncol.,i 25: 1989. 161. Jordan, V. C., and Koch, R. Regulation of prolactin synthesis in vitro by estrogenic and antiestrogemc derivatives of estradici and estrone. Endocrinology, 124: 1717-1726, 1989. 162. Robinson, S. P., and Jordan, V. C. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure. Eur. J. Cancer Clin. Oncol., 25:493-497, 1989. '63. Jordan, V. C. Chemosuppression of breast cancer with tamoxifen: laboratoI7 evidence and future clinical investigations. Cancer Invest., 6: 5-11, ÃŒ?â€¢â€¢' i , â€¢ -â€¢<â€¢, , ,, 164. Â¿. Cuzik, and Baum, M. Tamoxifen and contralateral breast cancer. Lancet, 282 J., 1985 ,65 Powle's T Â¿ Hardy j R Ash,ey s E Farringtoni G. H., Cosgrove, D., Davey, J. B., Dowsett, M., McKinna, J. A., Wash, A. G., Sinnett, H. p., Tillyer, C. R., and Treleaven, J. G. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br. J. Cancer, 60: 126-131, 1989. 4189 Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research. Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture Leonard J. Lerner and V. Craig Jordan Cancer Res 1990;50:4177-4189. Updated version E-mail alerts Reprints and Subscriptions Permissions Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/50/14/4177 Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at email@example.com. To request permission to re-use all or part of this article, contact the AACR Publications Department at firstname.lastname@example.org. Downloaded from cancerres.aacrjournals.org on April 28, 2017. © 1990 American Association for Cancer Research.